JP2019529500A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529500A5
JP2019529500A5 JP2019517777A JP2019517777A JP2019529500A5 JP 2019529500 A5 JP2019529500 A5 JP 2019529500A5 JP 2019517777 A JP2019517777 A JP 2019517777A JP 2019517777 A JP2019517777 A JP 2019517777A JP 2019529500 A5 JP2019529500 A5 JP 2019529500A5
Authority
JP
Japan
Prior art keywords
cancer
group
alkyl
compound according
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019517777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529500A (ja
JP7184761B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/054694 external-priority patent/WO2018067424A1/en
Publication of JP2019529500A publication Critical patent/JP2019529500A/ja
Publication of JP2019529500A5 publication Critical patent/JP2019529500A5/ja
Priority to JP2022158467A priority Critical patent/JP2022173493A/ja
Application granted granted Critical
Publication of JP7184761B2 publication Critical patent/JP7184761B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2019517777A 2016-10-03 2017-10-02 アデノシン５’－ヌクレオチダーゼの阻害剤 Active JP7184761B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022158467A JP2022173493A (ja) 2016-10-03 2022-09-30 アデノシン５’－ヌクレオチダーゼの阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403598P 2016-10-03 2016-10-03
US62/403,598 2016-10-03
PCT/US2017/054694 WO2018067424A1 (en) 2016-10-03 2017-10-02 Inhibitors of adenosine 5'-nucleotidase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022158467A Division JP2022173493A (ja) 2016-10-03 2022-09-30 アデノシン５’－ヌクレオチダーゼの阻害剤

Publications (3)

Publication Number Publication Date
JP2019529500A JP2019529500A (ja) 2019-10-17
JP2019529500A5 true JP2019529500A5 (enExample) 2021-04-15
JP7184761B2 JP7184761B2 (ja) 2022-12-06

Family

ID=61831914

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019517777A Active JP7184761B2 (ja) 2016-10-03 2017-10-02 アデノシン５’－ヌクレオチダーゼの阻害剤
JP2022158467A Withdrawn JP2022173493A (ja) 2016-10-03 2022-09-30 アデノシン５’－ヌクレオチダーゼの阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022158467A Withdrawn JP2022173493A (ja) 2016-10-03 2022-09-30 アデノシン５’－ヌクレオチダーゼの阻害剤

Country Status (6)

Country Link
US (3) US11058704B2 (enExample)
EP (1) EP3518934A4 (enExample)
JP (2) JP7184761B2 (enExample)
CN (1) CN110049767B (enExample)
TW (1) TWI781960B (enExample)
WO (1) WO2018067424A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11058704B2 (en) 2016-10-03 2021-07-13 Arcus Biosciences, Inc. Inhibitors of adenosine 5′-nucleotidase
US20200115404A1 (en) * 2017-03-31 2020-04-16 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2019129059A1 (zh) * 2017-12-29 2019-07-04 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
CN112004541A (zh) * 2018-03-09 2020-11-27 艾库斯生物科学有限公司 肠道外给药的免疫增强药物
AU2019261976B2 (en) * 2018-04-30 2025-01-23 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2019232319A1 (en) 2018-05-31 2019-12-05 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
WO2020047082A1 (en) * 2018-08-28 2020-03-05 Eternity Bioscience Inc. Cd73 inhibitors and therapeutic uses thereof
KR20210114963A (ko) 2019-01-11 2021-09-24 오메로스 코포레이션 암을 치료하기 위한 방법 및 조성물
WO2020151707A1 (zh) * 2019-01-22 2020-07-30 江苏恒瑞医药股份有限公司 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用
KR20210137162A (ko) 2019-03-12 2021-11-17 아르커스 바이오사이언시즈 인코포레이티드 종양유전자-유발 암의 치료
US20220160747A1 (en) * 2019-03-20 2022-05-26 Korea Research Institute Of Chemical Technology Pharmaceutical composition comprising novel azolopyrimidine heterocyclic compound as active ingredient
CN113874397A (zh) * 2019-03-29 2021-12-31 艾库斯生物科学有限公司 利用鉴定的腺苷指纹治疗癌症
WO2020210970A1 (en) * 2019-04-16 2020-10-22 Bioardis Llc Imidazotriazine derivatives as cd73 inhibitors
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑，其製備方法和應用
US20220251134A1 (en) 2019-06-14 2022-08-11 Southern Research Institute 2,4,7-substituted-7-deaza-2'-deoxy-2'-fluoroarabinosyl nucleoside and nucleotide pro-drugs and uses thereof
US20220331343A1 (en) * 2019-07-16 2022-10-20 Oric Pharmaceuticals, Inc. Cd73 inhibitors
WO2021040356A1 (en) * 2019-08-23 2021-03-04 Kainos Medicine, Inc. C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
PT4051688T (pt) 2019-10-30 2025-06-30 Oric Pharmaceuticals Inc Inibidores de cd73
EP4121409A1 (en) 2020-03-19 2023-01-25 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
PE20231078A1 (es) 2020-06-02 2023-07-17 Arcus Biosciences Inc Anticuerpos anti-tigit
US20240226115A1 (en) 2021-05-21 2024-07-11 Arcus Biosciences, Inc. Axl inhibitor compounds
WO2022246177A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl compounds
IL312348A (en) 2021-10-29 2024-06-01 Arcus Biosciences Inc HIF-2ALPHA inhibitors and methods of using it
CA3256033A1 (en) 2022-04-13 2023-10-19 Arcus Biosciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2
CA3256561A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and their uses
CN115181148B (zh) * 2022-07-12 2023-07-14 南京工业大学 一种基于虫草素经衍生化具有抗肿瘤效应的化合物
JP7679129B2 (ja) * 2022-07-12 2025-05-19 南京工▲業▼大学 コルジセピンの誘導体化による抗腫瘍効果を有する化合物
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4587001A1 (en) 2022-09-14 2025-07-23 Arcus Biosciences, Inc. Dispersions of etrumadenant
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
WO2024226872A2 (en) * 2023-04-26 2024-10-31 Lakewood Amedex, Inc. Substituted bicyclic heterocycle compounds, compositions, and uses thereof
WO2024233360A1 (en) 2023-05-05 2024-11-14 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US20250011318A1 (en) 2023-05-25 2025-01-09 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
WO2025076299A1 (en) 2023-10-06 2025-04-10 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025096979A1 (en) 2023-11-02 2025-05-08 Arcus Biosciences, Inc. Thiazole compounds as kit inhibitors and methods of use thereof
WO2025113498A1 (zh) * 2023-12-01 2025-06-05 无锡和誉生物医药科技有限公司 一种cd73抑制剂碱式盐及其制备方法和应用
CN117562915A (zh) * 2023-12-05 2024-02-20 中国药科大学 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same
CN119552122B (zh) * 2025-01-27 2025-05-09 北京悦康科创医药科技股份有限公司 5'-磷酸酯修饰核苷及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468119A1 (en) * 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Novel carbocyclic analogs of certain nucleosides
US6617439B1 (en) * 2000-06-09 2003-09-09 Bar-Ilan University C8-substituted purine nucleotide analogs
WO2004096233A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
US7495006B2 (en) 2004-12-10 2009-02-24 Emory University 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
WO2006130217A2 (en) 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
EP2021350B1 (en) * 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
CN101528260A (zh) * 2006-10-26 2009-09-09 协和发酵麒麟株式会社 肠易激综合症治疗剂
WO2008121261A2 (en) * 2007-03-28 2008-10-09 Vioquest Pharmaceuticals, Inc. Prodrugs of triciribin suitable for treatment of tumors and cancer
HK1203513A1 (en) * 2012-03-21 2015-10-30 艾丽奥斯生物制药有限公司 Methods of preparing substituted nucleotide analogs
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2015164573A1 (en) 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer
US11058704B2 (en) 2016-10-03 2021-07-13 Arcus Biosciences, Inc. Inhibitors of adenosine 5′-nucleotidase
US20200115404A1 (en) * 2017-03-31 2020-04-16 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2019529500A5 (enExample)
JP2019535720A5 (enExample)
JP2019501223A5 (enExample)
JP2020111618A5 (enExample)
JP2017525753A5 (enExample)
JP2021167351A5 (enExample)
JP2010539095A5 (enExample)
JP2017538678A5 (enExample)
HRP20231155T1 (hr) Modulatori 5'-nukleotidaze, ecto i njihova uporaba
JP2020519664A5 (enExample)
IL295569A (en) Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
JP2017537080A5 (enExample)
JPWO2020023846A5 (enExample)
JP2017538677A5 (enExample)
JPWO2021188769A5 (enExample)
JP2018138577A5 (enExample)
JP2016523973A5 (enExample)
JP2017509689A5 (enExample)
RU2018128334A (ru) Ингибиторы индоламин-2,3-диоксигеназы (ido)
JP2014193925A5 (enExample)
RU2015143717A (ru) 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия
JP2019529444A5 (enExample)
JPWO2020102646A5 (enExample)
JP2016538344A5 (enExample)
JP2016053042A5 (enExample)